Azenta, Inc. (AZTA) Dividend History

Azenta, Inc. (AZTA) is a global provider of life science and laboratory automation solutions. The company specializes in research and development services, sample management, and laboratory products, supporting the pharmaceutical, biotech, and healthcare industries. Azenta focuses on enabling scientific discovery through innovative technology and streamlined workflows.

200 Summit Drive, Burlington, MA, 01803
Phone: (978) 262-2400
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
December 23, 2021 $0.10 12/02/2021 12/03/2021
September 24, 2021 $0.10 09/02/2021 09/03/2021
June 25, 2021 $0.10 06/03/2021 06/04/2021
March 26, 2021 $0.10 03/04/2021 03/05/2021
December 17, 2020 $0.10 12/03/2020 12/04/2020
Show more

Dividends Summary

  • Azenta, Inc. has issued 42 dividend payments over the past 10 years
  • The most recent dividend was paid 1262 days ago, on December 23, 2021
  • The first recorded dividend was paid on September 30, 2011
  • The highest dividend payout was $0.10 per share
  • The average dividend over this 10 year span is $0.09 per share
  • Azenta, Inc. has increased its dividend payments by 25.00% since 2011

Company News

  • Biobanking Market to Reach Market Valuation of USD 95.5 Billion by 2031 | SkyQuest Technology

    The global biobanking market is projected to reach a valuation of USD 95.5 billion by 2031, growing at a CAGR of 6.8% during the forecast period. The growth is driven by the rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic illnesses worldwide.

    Benzinga
  • Biobanking Market to Reach Market Valuation of USD 95.5 Billion by 2031 | SkyQuest Technology

    The global biobanking market is expected to grow from $72 billion in 2023 to $95.5 billion by 2031, driven by rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic diseases. The disease-based biobanks and population-based biobanks segments are expected to lead the market.

    GlobeNewswire Inc.
    Featured Companies: AVTR
  • Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider

    The antibody production market is expected to grow significantly due to the increasing demand for targeted therapies and advancements in biotechnology, such as recombinant DNA technology and high-throughput screening methods.

    GlobeNewswire Inc.
    Featured Companies: A BIO BIO.B ILMN PACB PKI PRPH QGEN TMO
  • Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop - Zacks Investment Research

    Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.

    Zacks Investment Research
    Featured Companies: HAE HIMS HYPR
  • Decoding 5 Analyst Evaluations For Azenta

    Throughout the last three months, 5 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Azenta, presenting an average target of $64.2, a high estimate of $75.00, and a low estimate of $53.00. A decline of 3.46% from the prior average price target is evident in the current average. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Azenta is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Vijay Kumar Evercore ISI Group Raises In-Line $53.00 $52.00 David Saxon Needham Lowers Buy $69.00 $75.00 David Saxon Needham Maintains Buy $75.00 $75.00 Vijay Kumar Evercore ISI Group Lowers In-Line $60.00 $64.00 Matthew Stanton Jefferies Announces Hold $64.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

    Benzinga
Dividend data last updated 06/07/2025 20:38:46 UTC